HOME > Investors > Press Releases
2016-08-02
VM BioPharma Announces Korea Food and Drug Administration Approval of Phase 2 Clinical Trial for Investigational Gene Therapy VM202 in Ischemic Heart Disease
2016-09-08
ViroMed proceeding with the World’s first phase III gene therapy clinical trial for diabetic peripheral neuropathy (DPN)
2016-08-26
(2016.08.25) Nomura Securities - Korea Healthcare and Pharmaceuticals - Fighting Diabetes
2016-07-06
2016.06 (IR letter) Business Updates
2016-06-28
VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy
1 2 3 4 5 6 7 8 9 10